EGFR and head and neck squamous cell carcinoma: For instance, Cetuximab, an anti-EGFR therapy, in combination with radiotherapy, is approved for locally advanced, recurrent or metastatic HNSCC since EGFR overexpression is associated with high local recurrence rates [14,15].